• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should BD’s Class I Spinal Tray Recalls Over Supplier Issues Require Action From Becton Dickinson (BDX) Investors?

    Simply Wall St·06/20/2026 19:29:21
    Listen to the news
    • In April 2026, Becton Dickinson & Company initiated multiple voluntary FDA Class I sub-recalls of BD Spinal Tray devices nationwide after an inspection of supplier Huons Co Ltd. found serious quality deficiencies in anesthetic components.
    • While quantities are relatively modest in unit terms, the recalls touch a wide range of catalog numbers and states, raising questions about quality oversight across Becton Dickinson’s spinal anesthesia tray supply chain.
    • We’ll now examine how these Class I spinal tray recalls tied to supplier quality issues may affect Becton Dickinson’s broader investment narrative.

    Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

    Becton Dickinson Investment Narrative Recap

    To own BD, you need to believe in its ability to compound earnings from a largely consumables-based portfolio while managing regulatory and supply chain complexity. The recent Class I spinal tray sub-recalls tied to Huons highlight quality oversight as a nearer term operational risk, but the affected volumes appear modest relative to BD’s overall scale, so the most important near term catalysts around margin execution and the planned Biosciences/Diagnostics separation are, for now, unlikely to be materially altered.

    Among recent announcements, the May 7, 2026 results and reaffirmation of low single digit plus GAAP revenue growth for fiscal 2026 are most relevant. They frame how investors were already thinking about modest top line progress and margin work before the spinal tray recalls surfaced, and they provide a reference point for assessing whether any additional regulatory, remediation, or supply chain costs from these Class I actions could incrementally weigh on BD’s earnings path.

    Yet beneath the headline recall, investors should also be aware that...

    Read the full narrative on Becton Dickinson (it's free!)

    Becton Dickinson's narrative projects $21.1 billion revenue and $1.8 billion earnings by 2029. This requires a 1.8% yearly revenue decline and about a $0.2 billion earnings increase from $1.6 billion today.

    Uncover how Becton Dickinson's forecasts yield a $181.23 fair value, a 26% upside to its current price.

    Exploring Other Perspectives

    BDX 1-Year Stock Price Chart
    BDX 1-Year Stock Price Chart

    Compared with the consensus view, the lowest analysts were already cautious, assuming revenue would shrink to about US$20,000,000,000 by 2029 and earnings reach only US$1,800,000,000, and they focus heavily on ongoing regulatory scrutiny and quality control challenges that news like the Huons related spinal tray recalls could make more central to your own view of BD’s risk profile.

    Explore 3 other fair value estimates on Becton Dickinson - why the stock might be worth just $181.23!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Contemplating Other Strategies?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.